Pricing Log in Create free account

Scribe Therapeutics Inc. (SCTX) vs X4 Pharmaceuticals, Inc. (XFOR)

Scribe Therapeutics Inc. and X4 Pharmaceuticals, Inc. are both Biotechnology companies. Scribe Therapeutics Inc. and X4 Pharmaceuticals, Inc. are of similar size ($304.4M and $293.1M). Across the 5 metrics below, Scribe Therapeutics Inc. leads on 3 and X4 Pharmaceuticals, Inc. on 2.

Valuation

Metric SCTX XFOR Biotechnology median
P/E — n/m 10.60
P/S n/m 23.50 9.40
P/B n/m 2.87 2.13
Price to free cash flow n/m 16.91 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 17.02 9.02
Earnings yield — (21.26%) (32.88%)
Free cash flow yield 0.00% 5.91% (23.13%)

Profitability

Metric SCTX XFOR Biotechnology median
Gross margin — 81.77% 68.51%
Operating margin — (473.95%) 0.00%
Net margin — (474.74%) 0.00%
Free cash flow margin — (478.16%) 0.00%
Return on equity — (80.32%) (51.96%)
Return on assets — (40.73%) (46.06%)
Return on invested capital 0.00% (178.23%) 0.00%

Growth

Metric SCTX XFOR Biotechnology median
Revenue growth (TTM) — (50.08%) 6.76%
EPS growth (last fiscal year) — 67.23% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric SCTX XFOR Biotechnology median
Debt to equity 0.00 0.55 0.00
Current ratio 0.57 13.22 4.97
Net debt to EBITDA 0.00 2.06 1.01

Dividend

Metric SCTX XFOR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric SCTX XFOR Biotechnology median
Market cap 293.06m 304.38m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack